Pacific Biosciences of California, Inc. (PACB) Posts Q3 EPS Loss of $0.54, Sales Top Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts PACB Hot Sheet
Join SI Premium – FREE
Pacific Biosciences of California, Inc. (NASDAQ: PACB) reported Q3 EPS of ($0.54), $0.05 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $10.52 million versus the consensus estimate of $9.73 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PacBio and Verily Health announce multi-year genomics collaboration
- Balchem Corp. (BCPC) Tops Q3 EPS by 14c
- SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
